trial

Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms (FRS) on Schizophrenia

NCTId NCT03284138
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 31 (actual)
Sponsored by Assistance Publique - Hôpitaux de Paris
Primary completion 2023-03-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
31 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2018-08-03
Primary completion
2023-03-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
rTMS treatment

Sponsors

Assistance Publique - Hôpitaux de ParisLead Sponsor

Investigators

1
Aurely Ameller, MD, PhDPrincipal Investigator

Sites

1 total
Colombes, France

Facts & assertions

4 sourced
Enrollment
31
Phase
NA
Primary Completion Date
2023-03-02
Status
COMPLETED
relationships
The graph out of here
drug
rTMS treatment
drug
lead_sponsor
Assistance Publique - Hôpitaux de Paris
company
indication
Schizophrenia Patients With First Rank Symptoms
indication
Schizophrenia
indication
investigator
Aurely Ameller, MD, PhD
person